New Zealand markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.1400-0.0600 (-1.43%)
As of 10:00AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 624.24M
Enterprise value 511.82M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.15
Price/book (mrq)6.85
Enterprise value/revenue 8.76
Enterprise value/EBITDA -7.71

Trading information

Stock price history

Beta (5Y monthly) 1.32
52-week change 3-32.26%
S&P500 52-week change 321.08%
52-week high 311.3100
52-week low 31.9950
50-day moving average 38.5624
200-day moving average 34.9168

Share statistics

Avg vol (3-month) 32.44M
Avg vol (10-day) 33.47M
Shares outstanding 5148.63M
Implied shares outstanding 6148.63M
Float 8126.72M
% held by insiders 13.68%
% held by institutions 150.11%
Shares short (15 Apr 2024) 414.65M
Short ratio (15 Apr 2024) 48
Short % of float (15 Apr 2024) 410.31%
Short % of shares outstanding (15 Apr 2024) 49.85%
Shares short (prior month 15 Mar 2024) 49.16M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -138.15%
Operating margin (ttm)-135.46%

Management effectiveness

Return on assets (ttm)-25.66%
Return on equity (ttm)-127.64%

Income statement

Revenue (ttm)58.44M
Revenue per share (ttm)0.73
Quarterly revenue growth (yoy)5.20%
Gross profit (ttm)N/A
EBITDA -79.4M
Net income avi to common (ttm)-80.74M
Diluted EPS (ttm)-1.0200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)195.81M
Total cash per share (mrq)1.32
Total debt (mrq)83.39M
Total debt/equity (mrq)91.50%
Current ratio (mrq)6.66
Book value per share (mrq)0.79

Cash flow statement

Operating cash flow (ttm)-70.23M
Levered free cash flow (ttm)-49.44M